@Antti_Luiro ja @Frans-Mikael_Rostedt har gjort en utmärkt kvalitativ analys som dessutom är gratis! Inderes Aiforia Technologies: Direction continues upward - Inderes Aiforia’s H2 was largely in line with our expectations and the company’s sales pipeline is still promising. We still consider the company’s competitive position as good and if Aiforia continues winning customers as expected, the potential will... Aiforia’s H2 was largely in line with our expectations and the company’s sales pipeline is still promising. We still consider the company’s competitive position as good and if Aiforia continues winning customers as expected, the potential will gradually begin to emerge more clearly in revenue. On the other hand, poor growth predictability and elevated financial risks argue for some caution in pricing the potential.

Analytiker @Antti_Luiro ja @Frans-Mikael_Rostedt & En ny analys av det mycket intressanta företaget Aiforia We reiterate our EUR 4.6 target price and raise our recommendation to Accumulate (was Reduce). Building of Aiforia’s growth continues and a positive news flow is expected from the company, especially on the sales front, but also on regulatory approvals progressing in Europe. The company’s customer gains have brought predictability to growth, although forecasting risks, especially in terms of growth timing and in the long term also concerning the revenue level, remain high. We believe Aiforia has clear preconditions to grow into one of the long-term winners in its market and after the share price drop (-12%), we find the risk/reward ratio attractive even within a year. Inderes Aiforia: We expect the positive news flow to continue - Inderes Aiforia’s growth continues and a positive news flow is expected from the company, especially on the sales front, but also on regulatory approvals progressing in Europe.

This is an exciting company; many see a lot of upside potential… but there are risks as well. Aiforia’s revenue growth stalled in the first half of the year, particularly in the US, although recent months’ customer wins suggest that the company is continuing to capture the market. Our near-term forecasts have been reduced significantly and we now see a more likely need for additional capital, but customer wins and good sales prospects have improved visibility on revenue growth. After the share price increase (+17%), we think the stock looks quite correctly priced. We reiterate our EUR 4.6 target price and switch our recommendation to Reduce (previous Accumulate). Inderes Aiforia H1'24: Growth is still gathering momentum - Inderes Aiforia's revenue growth stalled in the first half of the year, particularly in the US, although recent months’ customer wins suggest that the company is continuing to capture the market.

Aiforias samarbete med Paris sjukhusdistrikt går framåt Inderes Aiforia's collaboration with Paris Hospital District moves forward - Inderes he start of the collaboration was announced earlier this spring, so the press release comes as no surprise, although the agreement announced now provides a concrete indication of the first steps of the collaboration. According to the release,...

Here is some recent news about Aiforia. Fimlab Laboratories Ltd, Finland’s largest healthcare technology company, has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions. The value of the first order is approximately EUR 300,000 for the first year, which is some 7% of our 2024 revenue forecast. The order and the concrete launch of the collaboration again support Aiforia’s strong growth prospects. Inderes Aiforia will provide AI solutions for breast and prostate cancer diagnostics... Fimlab Laboratories Ltd, Finland's largest healthcare technology company, has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions.

Här är analytikerns färska kommentarer om företagets nya samarbetsarrangemang. The regional health management of Castilla y León in Spain has chosen Aiforia as its partner for AI-based diagnostics. The collaboration involves the use of selected Aiforia AI solutions for the analysis of tissue samples, e.g., from breast, prostate, and lung cancer patients. The total value of the contract for Aiforia is around 500 TEUR over three years, which means an annual billing of around 167 TEUR. This makes the contract quite significant for the company, but achieving the growth forecasts for the coming years will obviously require similar successes. Inderes Aiforia selected to provide AI-assisted diagnostics solutions in Castilla y... The regional health management of Castilla y León in Spain has chosen Aiforia as its partner for AI-based diagnostics. The collaboration involves the use of selected Aiforia AI solutions for the analysis of tissue samples, e.g., from breast,...

Förra veckans aktieemission på 10 miljoner euro har stärkt Aiforias finansiella situation. Med tanke på positiva försäljningsnyheter verkar företaget fortsätta mot en stark position på sina snabbt framväxande marknader, även om den svaga förutsägbarheten i tillväxten fortfarande talar för en viss försiktighet vid prissättningen av potentialen. Inderes Aiforia: Growth is now built with better capitalization - Inderes With the 10 MEUR share issue last week, Aiforia’s financial situation strengthened. In light of positive sales news, the company seems to continue moving toward a strong position in its rapidly emerging markets, although weak growth predictability...